R&D / revenue
Separately reported research and development expense divided by revenue.
How it is calculated
Calculated as rd / revenue, from Research & development, Revenue. A figure the company reported directly always outranks this calculation, and it is withheld when its inputs come from different filing vintages.
Highest reported
| Company | R&D / revenue | Period end |
|---|---|---|
| GNLX GENELUX Corp | 248137.5% | 2025-12-31 |
| SNTI Senti Biosciences Holdings, Inc. | 170845.5% | 2025-12-31 |
| ACHR Archer Aviation Inc. | 164633.3% | 2025-12-31 |
| ALT Altimmune, Inc. | 162029.3% | 2025-12-31 |
| RPMT REGO PAYMENT ARCHITECTURES, INC. | 148168.2% | 2025-12-31 |
| ATOS ATOSSA THERAPEUTICS, INC. | 134220.3% | 2015-12-31 |
| ADTX Aditxt, Inc. | 99972.9% | 2025-12-31 |
| INO INOVIO PHARMACEUTICALS, INC. | 82957.4% | 2025-12-31 |
| LUDG LUDWIG ENTERPRISES, INC. | 76323.0% | 2024-12-31 |
| HSCS HeartSciences Inc. | 65733.1% | 2026-04-30 |
| CNTB Connect Biopharma Holdings Ltd | 59059.4% | 2025-12-31 |
| INMB Inmune Bio, Inc. | 41318.0% | 2025-12-31 |
| OGEN ORAGENICS INC | 41140.4% | 2023-12-31 |
| GMER GOOD GAMING, INC. | 38730.3% | 2024-12-31 |
| CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 37663.3% | 2025-12-31 |
Latest annual period for each company; fiscal year ends differ. Figures are the filers’ own.
Every figure on this site links to the filing it came from. See the methodology for how periods and concepts are chosen, and the disclosures for what the data is not.